Mersana Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Mersana Therapeutics

03/11/2023 18:44

* Mersana Therapeutics Inc  MRSN.OQ   MRSN.O  is expected
to show
a rise in quarterly revenue when it reports  results 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 67.8% increase in revenue to $9.35 million from $5.57 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Mersana
Therapeutics Inc
is for a loss of 36 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mersana
Therapeutics Inc is $1.5​, above​ its last closing price
of $1.28. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.37       -0.44      -0.47     Missed  -6.5
 Mar. 31 2023  -0.40       -0.44      -0.52     Missed  -19.3
 Dec. 31 2022  -0.47       -0.50      -0.44     Beat    12.8​
 Sep. 30 2022  0.04        -0.09      -0.61     Missed  -577.8
 ​​Jun.        -0.53       -0.52      -0.55     Missed  -5.8
 30 2022                                                
 Mar. 31 2022  -0.32       -0.32      -0.59     Missed  -85.2​
 Dec. 31 2021  -0.66       -0.67      -0.68     Missed  -1.7
 Sep. 30 2021  -0.58       -0.58      -0.63     Missed  -8.6
 This summary was machine generated November 3 at 18:44 GMT.  All
figures in US dollars  unless otherwise stated